Universität zu Köln

Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan ORCID: 0000-0002-7785-2565, Duehrsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengass, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, Lokhorst, Henk, Martin, Hans, Goerner, Martin, Hoffmann, Martin, Lindemann, Hans-Walter, Bernhard, Helga, Blau, Igor W., Scheid, Christof, Besemer, Britta, Weisel, Katja C., Haenel, Mathias, Duerig, Jan and Goldschmidt, Hartmut (2021). Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J., 11 (1). LONDON: SPRINGERNATURE. ISSN 2044-5385

Goldschmidt, Hartmut, Mai, Elias K., Duerig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Merz, Maximilian, Munder, Markus, Lindemann, Hans-Walter, Huegle-Doerr, Barbara, Tichy, Diana, Giesen, Nicola, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Rabold, Bernhard, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc S., Blau, Igor W., Haenel, Mathias and Salwender, Hans J. (2020). Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia, 34 (7). S. 1853 - 1866. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Klein, Eva-Maria, Tichy, Diana, Salwender, Hans J., Mai, Elias K., Duerig, Jan, Weisel, Katja C., Benner, Axel, Bertsch, Uta, Akhavanpoor, Mabast, Besemer, Britta, Munder, Markus, Lindemann, Hans-Walter, Hose, Dirk, Seckinger, Anja, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Raab, Marc S., Blau, Igor W., Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2021). Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 13 (19). BASEL: MDPI. ISSN 2072-6694

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans J., Munder, Markus, Gerecke, Christian, Duehrsen, Ulrich, Brossart, Peter, Neben, Kai, Hillengass, Jens, Raab, Marc S., Merz, Maximilian, Baertsch, Marc-Andrea, Jauch, Anna, Hose, Dirk, Martin, Hans, Lindemann, Hans-Walter, Blau, Igor W., Scheid, Christof, Weisel, Katja C. and Goldschmidt, Hartmut (2019). Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia, 33 (1). S. 258 - 262. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Mai, Elias K., Miah, Kaya, Bertsch, Uta, Duerig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Haenel, Mathias, Benner, Axel, Salwender, Hans J. and Goldschmidt, Hartmut . Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Mai, Elias Karl ORCID: 0000-0002-6226-1252, Kunz, Christina, Bertsch, Uta, Salwender, Hans-Juergen, Pfreundschuh, Michael, Duehrsen, Ulrich, Brossart, Peter, Peter, Norma, Neben, Kai, Hielscher, Thomas, Hillengass, Jens, Martin, Hans, Lindemann, Hans Walter, Scheid, Christof, Weisel, Katja C., Blau, Igor W. and Goldschmidt, Hartmut (2015). Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Merz, Maximilian, Jauch, Anna, Hielscher, Thomas, Mai, Elias K., Seckinger, Anja, Hose, Dirk, Bertsch, Uta, Neben, Kai, Raab, Marc S., Salwender, Hans ORCID: 0000-0001-7803-0814, Blau, Igor W., Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Scheid, Christof, Haenel, Mathias, Weisel, Katja, Goldschmidt, Hartmut and Hillengass, Jens (2017). Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica, 102 (8). S. 1432 - 1439. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Merz, Maximilian, Salwender, Hans, Haenel, Mathias, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Mai, Elias Karl ORCID: 0000-0002-6226-1252, Hose, Dirk, Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo G. H., Gerecke, Christian, Lindemann, Hans Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan and Goldschmidt, Hartmut (2014). Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma - Subgroup Analysis from the GMMG-MM5 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Merz, Maximilian, Salwender, Hans ORCID: 0000-0001-7803-0814, Haenel, Mathias, Mai, Elias K., Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Hillengass, Jens, Raab, Marc S., Schurich, Baerbel, Munder, Markus, Brossart, Peter, Gerecke, Christian, Lindemann, Hans-Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan and Goldschmidt, Hartmut (2016). Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica, 101 (12). S. E485 - 3. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Merz, Maximillan, Salwender, Hans-Juergen, Haenel, Mathias, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Mai, Elias Karl ORCID: 0000-0002-6226-1252, Hose, Dirk, Schurich, Baerbel, Munder, Markus, Brossart, Peter, Gerecke, Christian, Lindemann, Hans Walter, Zeis, Matthias, Weisel, Katja C., Duerig, Jan and Goldschmidt, Hartmut (2015). Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 19. LONDON: BMC. ISSN 1471-2407

Salwender, Hans, Elmaagacli, Ahmet, Merz, Maximilian, Miah, Kaya, Benner, Axel, Haenel, Mathias, Jehn, Christian, Mai, Elias K., Bertsch, Uta, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Raab, Marc S., Luntz, Steffen P., Besemer, Britta, Munder, Markus, Brossart, Peter, Fuhrmann, Stephan, Lindemann, Hans-Walter, Weisel, Katja, Duerig, Jan and Goldschmidt, Hartmut (2021). Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia, 35 (10). S. 3007 - 3012. LONDON: SPRINGERNATURE. ISSN 1476-5551

Scheid, Christof, Blau, Igor W., Sellner, Leopold, Ratsch, Boris A. and Basic, Edin . Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database. Eur. J. Haematol.. HOBOKEN: WILEY. ISSN 1600-0609

Sonneveld, Pieter, Salwender, Hans-Juergen, Van der Holt, Bronno, el Jarari, Laila, Bertsch, Uta, Blau, Igor W., Zweegman, Sonja, Weisel, Katja C., Vellenga, Edo, Pfreundschuh, Michael, Broijl, Annemiek, Scheid, Christof, Wittebol, Shulamiet, Bos, Gerard M. J., Stevens-Kroef, Marjan, Jauch, Anna, Potamianou, Anna, Hose, Dirk, Raymakers, Reinier, Schaafsme, Marinus, Kersten, Marie Jose, Kooy, Marinus van Marwijk, Duehrsen, Ulrich, Lindemann, Hans Walter, Brossart, Peter, Wijermans, Pierre, Lokhorst, Henk M. and Goldschmidt, Hartmut (2015). Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Weinhold, Niels, Salwender, Hans J., Cairns, David A., Raab, Marc S., Waldron, George, Blau, Igor W., Bertsch, Uta, Hielscher, Thomas, Morgan, Gareth J., Jauch, Anna, Davies, Faith E., Hanel, Mathias, Cook, Gordon ORCID: 0000-0003-1717-0412, Scheid, Christoph, Houlston, Richard ORCID: 0000-0002-5268-0242, Goldschmidt, Hartmut, Jackson, Graham and Kaiser, Martin F. (2021). Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica, 106 (10). S. 2754 - 2759. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078